A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.
News|Articles|August 31, 2026
Midsized Biotechs Strike MFN Drug Pricing Deals
Author(s)Maggie L. Shaw
Fact checked by: Giuliana Grossi
This extension to smaller drugmakers addresses a gap that has increasingly drawn attention from policy watchers.
Advertisement
Advertisement
Nine midsize pharmaceutical manufacturers have agreed to price outpatient drugs for state Medicaid programs in line with what they charge in other developed countries, the White House announced today,1 extending the administration’s Most Favored Nation (MFN) drug pricing campaign beyond the large drugmakers that have so far signed on to a tier of drugmakers that had largely sat outside these earlier deals.2
Related to this article
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
Older adults on Medicare report the best access to care among 10 countries but more cost-related problems and higher out-of-pocket spending.
Even when physicians prescribe guideline-preferred therapies, step therapy and prior authorization can delay or restrict access to CLL therapies.
The trade group says CMS lacks authority to impose GLOBE, which is set to begin January 1.
CMS finalized Transparency in Coverage updates as a researcher warns ghost rates and missing inpatient data limit payer price files.
Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.
Washington, DC, clinicians shared how order sets, pharmacist-led dosing, and better handoffs can close iron deficiency gaps in heart failure care.
Advertisement
Advertisement